Alectos Therapeutics is a private pharmaceutical company dedicated to the discovery and preclinical development of novel small-molecule therapeutics for neurological diseases. Alectos focuses on identifying and developing innovative disease-modifying strategies to address complex neurological conditions for which there are no effective treatments, including Alzheimer’s disease, Parkinson’s disease, and acute ischemic stroke.
The Alectos pipeline is directed towards the development of new agents to treat patients living with neurological disorders. Our glucocerebrosidase 2 (GBA2) program represents a disease-modifying strategy to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease, Niemann-Pick type C disease, and Batten disease. Our O-GlcNAcase (OGA) program focuses on the development of neuroprotective therapies to counteract the effects of cellular stress in the brain. Alectos partnered with Merck to pioneer the development of the first OGA inhibitor to enter clinical studies. This program has now returned to Alectos, and we are applying our broad intellectual property and deep knowledge in this space to advance our novel OGA inhibitors as disease-modifying treatments for neurodegenerative diseases including AD/PD, as well as for acute conditions such as ischemic stroke and traumatic brain injury. We welcome partnership inquiries regarding our OGA and GBA2 programs.
Company Details
- Employees
- 16
- Founded
- -
- Address
- 8999 Nelson Way, Burnaby,b.c. V5a 4b5,canada
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- alectos.com
- Keywords
- Drug discovery, Target validation, Small-molecule therapeutics, Alzheimer's Disease, Parkinson's Disease, Niemann-Pick Type C Disease, Batten Disease, Acute Ischemic Stroke, Traumatic Brain Injury.
- HQ
- Burnaby, B.C.
Alectos Therapeutics Inc. Questions
Alectos Therapeutics Inc.'s website is alectos.com
Alectos Therapeutics Inc.'s LinkedIn profile is https://ca.linkedin.com/company/alectos-therapeutics-inc
Alectos Therapeutics Inc. has
16 employees.
View email and phone details for 16
employees at Alectos Therapeutics Inc..
Alectos Therapeutics Inc.'s industry is
Pharmaceutical Manufacturing
Alectos Therapeutics Inc.'s top competitors are
Mint Pharmaceuticals,
Abcellera,
Cardiol Therapeutics Inc.,
Bold Therapeutics Inc.,
Augurex Life Sciences Corp.,
Nanovation Therapeutics™,
Acuitas Therapeutics,
Gandeeva Therapeutics,
Hls Therapeutics Inc.,
Providence Therapeutics.
Alectos Therapeutics Inc.'s categories are Pharmaceutical Manufacturing
Alectos Therapeutics Inc.'s founding year is 2007
